ABPI Logo
  • Developing medicines
    • General Election hub
    • Brexit
    • Life Sciences Industrial Strategy
    • Regulatory science
    • New Medicines & Data
    • Academic Collaboration, Education & Skills
    • Careers in the pharmaceutical industry
    • ABPI Medical Representatives Exam
    • Clinical trials - How the UK is researching medicines of the future
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • Rare diseases
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • We Won't Rest
    • Appropriate prescribing
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Facts and figures
  • Science and innovation
  • Number of infectious disease clinical trials - global

Number of infectious disease clinical trials - global

This therapeutic area records numbers of trials initiated in infectious diseases.  The UK is leading as a site for infectious diseases clinical research, behind the US.

Data was collected from Cortellis Clinical Trial Intelligence, Clarivate Analytics using the following criteria: trial start date (1st January 2012 – 31st December 2016), phase (I, II, III), and country (UK, Spain, Germany, France, Italy, Poland, USA, Canada, Australia, China, Brasil, South Africa, Switzerland and Japan). Only trials related to pharmaceutical drug development and molecular/biological entities were included. Only commercial trials were included. Collaborative trials were only included if one or more partners were a commercial organisation. All therapeutic areas were included in this analysis. This analysis focused on infectious disease only. Trials across multiple therapy areas were only included once. The therapy area in which they were included was determined by the trial’s main purpose for study.

Phase not specified trials were excluded.
Only trials related to pharmaceutical drug development and molecular/ biological entities were included.
Where a company was included as a sponsor or collaborator, the trial was included, even if an academic institution was also listed.
Trials across multiple therapy areas were only included in their main therapy area.

SOURCE: Cortellis Clinical Trial Intelligence from Clarivate Analytics

2012-2014 data accessed March – April 2017.

2015 data accessed December 2017.

2016-2017 data accessed December 2018.

Science and innovation

  • Global public funding of health R&D
  • UK health research expenditure
  • Worldwide pharmaceutical company R&D expenditure
  • PhRMA Members R&D expenditure in total and in the US only
  • Worldwide pharmaceutical company R&D expenditure by country
  • UK biopharma R&D expenditure (5 year trend)
  • UK R&D intensity by industry
  • Global pharmaceutical R&D expenditure by therapeutic area
  • Global pharmaceutical R&D expenditure along the development cycle
  • Probability of medicine’s success to market
  • Number of NMEs and NASs launched worldwide
  • Number of NMEs launched by active substance type
  • Regions of first launch of new molecular entities
  • Share of patients recruited to global studies
  • UK Clinical Trial Applications commercial and non-commercial
  • UK Clinical Trial applications by Phase
  • Number of Phase 1 trials - global
  • Number of Phase 2 trials - global
  • Number of Phase 3 trials - global
  • Number of cardio-metabolic clinical trials - global
  • Number of oncology clinical trials - global
  • Number of nervous system clinical trials - global
  • Number of immune disorders clinical trials - global
  • Number of infectious disease clinical trials - global
  • Methodology in clinical trial estimates

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2019
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.